
New RSV vaccine called Arexy approved for people aged 60 and older
Health Canada has authorized the first RSV vaccine for people aged 60 and older.
Doctors have been calling for the vaccine for this group, which is at a higher risk of becoming severely ill from the virus.
Drugmaker GSK says during clinical trials, the drug was 82 percent effective at lowering respiratory tract disease caused by RSV.
In Canada, RSV season usually starts in the fall, and ends in the spring.